|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease.
|
30939045 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
After adjustment for influencing factors and related lipids, only apoB-100 (odds ratio per one SD [OR], 1.39; 95% confidence interval [CI], 1.05-1.84) was independently associated with CAD while apoA-IV (OR, 0.74; 95% CI 0.58-0.95) indicated PAD.
|
30594773 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aim was to estimate the genotypic distribution and risk allele frequencies of 13 Coronary Artery Disease (CAD) risk Single Nucleotide Polymorphisms in loci identified by the CARDIoGRAMplusC4D consortium namely MIA3 rs17465637; 9p21 rs10757274; CXCL12 rs1746048; APOA5 rs662799; APOB rs1042031; LPA rs3798220; LPA 10455872; MRAS rs9818870; LPL rs328; SORT1 rs646776; PCSK9 rs11591147; APOE rs429358; APOE rs7412 in Pakistani PCAD patients and controls.
|
28705542 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the kinetics of Lp(a) and LDL apolipoprotein B-100 (apoB) particles in patients with elevated Lp(a) and coronary artery disease undergoing regular apheresis.
|
30447089 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease.
|
30779793 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals identified at metabolic risk should undergo 10-year global risk assessment for ASCVD or coronary heart disease to determine targets of therapy for reduction of apolipoprotein B-containing lipoproteins.
|
31365087 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predicting value of CAD manifested as sd-LDL > ox-LDL > apoB > non-HDL-C > LDL-C > Lp(a) [area under curve (AUC): sd-LDL 0.641; ox-LDL 0.640; apoB 0.611; non-HDL-C 0.587; LDL-C 0.583; Lp(a) 0.554; respectively].
|
29730953 |
2018 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to verify the possible influence of apolipoprotein B (ApoB: rs1042031 and rs693) and angiotensin-converting enzyme (ACE-ID: rs1799752) genotypes on the lipid profile and functional aerobic capacity, respectively, after an aerobic interval training (AIT) program in patients with CAD and/or cardiovascular risk factors.
|
29846435 |
2018 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TNF-α -308 (G/A), and TNF-β +252 (A/G) haplotype "GG" "AG" increased CAD risk significantly (GG haplotype, adjusted OR=2.6, CI 1.4-5.0, p=0.003 and AG haplotype OR=8.5, CI 2.2-33.35, p=0.002) after adjustments for age, sex, TC, TG, HDL, APOB, smoking and diet.
|
28739396 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postprandial triglycerides, TG-rich lipoprotein triglycerides, retinyl palmitate and apolipoprotein B48 to B100 ratio were measured before (following a 12-hour fasting period) and after a fat-tolerance test meal in a middle-aged, biracial subcohort without CVD (coronary heart disease (CHD) or stroke) from the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990-1993.
|
28191321 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study shows that the G allele carriers of BRCA2 rs9534275 were associated with increased serum TC and ApoB levels in the CAD patients and increased risk of CAD and IS.
|
28982360 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In stepwise multivariate logistic regression analysis, campesterol/TC and apoB48 concentrations were independent risk factors for de novo lesion progression in statin-treated CAD patients after PCI.
|
27487947 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individually, the single SNPs were not associated with CAD except APOB rs1042031 and FTO rs993969 (p = 0.01 and 0.009 respectively).
|
28167353 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sdLDL-C levels in the hyper-TG/-apoB group were 50% higher in patients with diabetes and CAD than those in controls.
|
28125987 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our equation to predict apoB levels showed MCVE risk prediction comparable to directly-measured apoB in high risk patients with previous coronary heart disease.
|
28830468 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease.
|
29246959 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography.
|
28506386 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease : A meta-analysis.
|
27637205 |
2016 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association Between Apolipoprotein B XbaI Polymorphism and Coronary Heart Disease in Han Chinese Population: A Meta-Analysis.
|
27172140 |
2016 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II.
|
27112212 |
2016 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the apolipoprotein B (apoB) gene have been reported to be associated with coronary heart disease (CHD).
|
26537298 |
2015 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, elevated apolipoprotein B and apolipoprotein A-I (ApoB/ApoA-I) ratio in plasma is also a risk factor for CAD.
|
25470794 |
2015 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor.
|
25070550 |
2014 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
mRNA profiles generated from blood macrophages in patients with CAD were used to infer transcription factor regulatory gene networks; Ldlr(-/-)Apob(100/100) mice were used to study the effects of Ldb2 deficiency on TEML activity and atherogenesis.
|
24925974 |
2014 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The plasma level of apolipoprotein B (apoB) is among the strongest risk factors for coronary artery disease.
|
24201112 |
2013 |